We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+18.77%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$5.81B
AUM Growth
+$81.2M
Cap. Flow
-$585M
Cap. Flow %
-10.08%
Top 10 Hldgs %
85.45%
Holding
128
New
20
Increased
23
Reduced
35
Closed
17

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$7.13M
2
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$6.85M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$5.62M
4
PRQR icon
ProQR Therapeutics
PRQR
+$5.19M
5
ARRY
Array Biopharma Inc
ARRY
+$5.11M

Top Sells

Rank Stock Value
1
GS icon
Goldman Sachs
GS
+$22.6M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$15M
3
ONC
BeOne Medicines Ltd
ONC
+$13M
4
BLUE
bluebird bio
BLUE
+$12.4M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$12.2M

Sector Composition

Rank Sector Weight
1 Consumer Staples 42.79%
2 Consumer Discretionary 22.09%
3 Healthcare 21.32%
4 Financials 0%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BUFF
1
DELISTED
Blue Buffalo Pet Products, Inc
BUFF
$2.48B 42.71%
87,460,875
– –
WW
2
DELISTED
WW International
WW
$1.28B 22.09%
29,443,300
– –
LXRX icon
3
Lexicon Pharmaceuticals
LXRX
$1.04B
$707M 12.18%
57,517,977
– –
BAC icon
4
CALL
Bank of America
BAC
$448B
$250M 4.3%
9,850,000
+1,400,000
+17% +$34M
GS icon
5
CALL
Goldman Sachs
GS
$304B
$47.4M 0.82%
200,000
-1,250,000
-86% -$282M
INCY icon
6
Incyte
INCY
$24.4B
$46.7M 0.8%
400,000
– –
BMY icon
7
CALL
Bristol-Myers Squibb
BMY
$132B
$41.4M 0.71%
650,000
-350,000
-35% -$20.4M
AGN
8
CALL
DELISTED
Allergan plc
AGN
$41M 0.71%
+200,000
New +$46.5M
WFC icon
9
CALL
Wells Fargo
WFC
$266B
$35.8M 0.62%
650,000
– –
AGIO icon
10
Agios Pharmaceuticals
AGIO
$2B
$30M 0.52%
450,000
-250,000
-36% -$15M
NKTR icon
11
Nektar Therapeutics
NKTR
$2.57B
$30M 0.52%
83,333
-10,000
-11% -$3.13M
ALNY icon
12
Alnylam Pharmaceuticals
ALNY
$30.4B
$29.4M 0.51%
250,000
-25,000
-9% -$2.13M
IBM icon
13
CALL
IBM
IBM
$223B
$29M 0.5%
209,200
– –
XLRN
14
DELISTED
Acceleron Pharma
XLRN
$26.1M 0.45%
700,000
– –
NBIX icon
15
Neurocrine Biosciences
NBIX
$15.3B
$24.5M 0.42%
400,000
-150,000
-27% -$7.91M
AAL icon
16
CALL
American Airlines Group
AAL
$9.97B
$23.7M 0.41%
+500,000
New +$24.2M
ONC
17
BeOne Medicines Ltd
ONC
$40.3B
$23.3M 0.4%
225,000
-175,000
-44% -$13M
BLK icon
18
CALL
Blackrock
BLK
$183B
$22.4M 0.39%
+50,000
New +$21.3M
C icon
19
CALL
Citigroup
C
$233B
$21.8M 0.38%
300,000
-200,000
-40% -$13.7M
MET icon
20
CALL
MetLife
MET
$61.9B
$20.8M 0.36%
400,000
-2,405,000
-86% -$117M
GILD icon
21
CALL
Gilead Sciences
GILD
$171B
$20.3M 0.35%
250,000
-1,000,000
-80% -$76.5M
INTC icon
22
CALL
Intel
INTC
$527B
$19M 0.33%
+500,000
New +$17.8M
AMGN icon
23
CALL
Amgen
AMGN
$226B
$18.6M 0.32%
+100,000
New +$17.7M
BMRN icon
24
BioMarin Pharmaceuticals
BMRN
$13.3B
$18.6M 0.32%
200,000
-50,000
-20% -$4.42M
BLUE
25
DELISTED
bluebird bio
BLUE
$18.5M 0.32%
10,422
-8,878
-46% -$12.4M
1
2 3 4 5

Similar funds

GP
Greenline Partners New York $930M AUM 29.59% 1-Year Est. Return
BCC
Biglari Capital Corp San Antonio, Texas $929M AUM 39.8% 1-Year Est. Return
FPI
Financial Plan Inc Bellingham, Washington $933M AUM
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
ICM
Innovator Capital Management Wheaton, Illinois $925M AUM 49.11% 1-Year Est. Return
OCM
OLP Capital Management Causeway Bay, Hong Kong $942M AUM 5.25% 1-Year Est. Return

Artal Group's Q3 2017 Portfolio in Review

As of Q3 2017, Artal Group held 128 positions worth $5.81B, up 1.4% from $5.72B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Artal Group withdrew a net $585M in Q3 2017, closing 17 positions and reducing 35 holdings. Its most notable exit was Goldman Sachs, an estimated $22.6M position sold in full.

By sector, the portfolio is most concentrated in Consumer Staples at 43% of assets, up from 35% a quarter earlier, followed by Consumer Discretionary and Healthcare.

Against the trend, Artal Group opened a new position in Achillion Pharmaceuticals worth $4.49M.

  • Artal Group's largest Q3 2017 buy was Achillion Pharmaceuticals: 1,000,000 shares worth $4.49M.
  • Artal Group added most to Clovis Oncology, Inc. in Q3 2017, an estimated $7.13M increase.
  • Artal Group's biggest Q3 2017 reduction was Agios Pharmaceuticals, cutting an estimated $15M.
  • Artal Group fully exited Goldman Sachs in Q3 2017, selling an estimated $22.6M.
  • Artal Group's ten largest holdings make up 85% of its $5.81B portfolio in Q3 2017.
  • Artal Group opened 20 new positions and closed 17 in Q3 2017.
  • Artal Group's portfolio value rose 1.4% quarter-over-quarter to $5.81B.

Based on Artal Group's 13F filing for Q3 2017, filed 8 Nov 2017.